Share Search
Visit the Share Search
C4X upbeat as its molecule progresses with Indivior
27th Sep 2019 15:39
(Sharecast News) - Drug discovery company C4X Discovery Holdings noted an announcement on Friday that the National Institutes of Health (NIH) in the United States has granted Indivior's application titled "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder'.
The AIM-traded firm said the application was under Funding Opportunity Announcement RFA-DA-19-002, which was dedicated to the development of medications to prevent and treat opioid use disorder and overdose.
"We are thrilled for Indivior to be awarded a NIH HEAL grant for clinical development of our molecule C4X3256, a non-opioid, highly-selective Orexin-1 receptor antagonist for the treatment of opioid use disorder," said C4X chief executive officer Dr Clive Dix.
"This award will enable Indivior to advance our molecule through phase 1 clinical evaluation as well as perform the toxicology and drug metabolism studies to enable phase 2studies.
"The support of NIH HEAL through this award not only validates our scientific expertise in drug discovery, but also our commercial strategy of out-licensing."
Dr Dix said the company was now focused on partnering its next molecule, NRF-2, for the treatment of sickle cell disease, and rapidly advancing its drug discovery programmes.
"We believe that C4X Discovery is building a credible and highly valuable portfolio of candidates for out-licensing to the pharma industry."
The AIM-traded firm said the application was under Funding Opportunity Announcement RFA-DA-19-002, which was dedicated to the development of medications to prevent and treat opioid use disorder and overdose.
"We are thrilled for Indivior to be awarded a NIH HEAL grant for clinical development of our molecule C4X3256, a non-opioid, highly-selective Orexin-1 receptor antagonist for the treatment of opioid use disorder," said C4X chief executive officer Dr Clive Dix.
"This award will enable Indivior to advance our molecule through phase 1 clinical evaluation as well as perform the toxicology and drug metabolism studies to enable phase 2studies.
"The support of NIH HEAL through this award not only validates our scientific expertise in drug discovery, but also our commercial strategy of out-licensing."
Dr Dix said the company was now focused on partnering its next molecule, NRF-2, for the treatment of sickle cell disease, and rapidly advancing its drug discovery programmes.
"We believe that C4X Discovery is building a credible and highly valuable portfolio of candidates for out-licensing to the pharma industry."